Literature DB >> 35371718

A Clinico-Epidemiological Study of Neurofibromatosis Type 1 and Its Relation to Quality of Life: A Cross-Sectional Study From India.

Aditi Mahajan1, Milind Patvekar1, Samruddhi Lote1, Mahendra Singh Deora1, Divya Poulose1, Jaya Madhurya Gogineni1, Krish Panikar2, Biswajit Chaklader3.   

Abstract

INTRODUCTION: Neurofibromatosis type 1 (NF1) is an inherited neuroectodermal abnormality with multisystem effects, which can have heavy psychological and physical burdens, especially in countries like India, wherein skin disease is significantly stigmatized. This study was performed to understand the clinical and epidemiological trends of NF1 at a tertiary care center in India and evaluate the association between clinical severity and quality of life in these patients.
METHODS: We conducted a cross-sectional study of 40 patients with NF1 over a period of two years at a tertiary hospital in western India. After obtaining consent, demographic and clinical information was collected from the patients and recorded in a pre-designed proforma. Quality of life was assessed by a validated Dermatology Life Quality Index (DLQI) questionnaire in languages understood by the patients and subsequently analyzed.
RESULTS: This study included 40 patients at a mean age of 28.6 years, with a slight male predominance. The most frequently occurring lesions were café-au-lait macules, followed by neurofibromas and intertriginous freckling. The mean DLQI score was 12.35, implying a large effect on most patients' lives. Questions related to self-consciousness, embarrassment, and the influence of skin lesions on clothing choices had the highest scores, indicating a significant effect on social perception.
CONCLUSION: NF1 has a profound impact on a patient's quality of life, as evidenced by the high DLQI scores in our patient cohort. The early identification and management of such patients can help prevent further deterioration of their quality of life.
Copyright © 2022, Mahajan et al.

Entities:  

Keywords:  dermatology; dlqi; india; neurofibromas; neurofibromatosis 1; quality of life (qol)

Year:  2022        PMID: 35371718      PMCID: PMC8940560          DOI: 10.7759/cureus.22376

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


Introduction

Neurofibromatosis type 1 (NF1) is an inherited neuroectodermal disease, primarily defined by the presence of six or more café‐au-lait macules, intertriginous freckles, two or more neurofibromas, Lisch nodules, bony defects like sphenoid dysplasia, and optic gliomas. It is an autosomal dominant condition with an estimated prevalence of one in 2500-3300 births, with 50% of cases occurring due to sporadic gene mutations [1]. Dermatological manifestations appear early in life and progress with age, but neurological features usually present at a later age [2]. The diagnosis of this condition is usually clinical, with genetic testing rarely being necessary. The cost and accessibility of genetic analysis, which is only available in a few selected tertiary care centers, are major barriers to the research and management of this disease in developing countries like India. NF1 is a chronic disease that puts a large amount of stress on patients, which adversely impacts their identity, mental well-being, self-confidence, and social relationships. Patients with incurable disorders must cope with multiple impediments to attain a feasible level of health, as well as adequate physical, intellectual, and social functioning [3]. Mental disorders like anxiety, personality disorders, depression, and suicidal tendencies are common in individuals with NF1 [4]. In severe cases, the persistence of cognitive impairment into adulthood hinders a patient's vocational performance, thereby hampering their quality of life (QoL) [5]. In a study of NF1 patients in Iran, Foji et al. found that NF1 affected all aspects of the patient’s life. In particular, perceived social alienation and difficulties regarding marriage and childbirth were present due to apprehensions regarding disease transmission to their progeny [6]. In short, dermatological diseases are a major contributor to the burden of non-fatal disease globally and influence different aspects of an individual's life [7]. Since the initial presentation of NF1 is mainly confined to the skin, patients usually consult dermatologists first. Thus, dermatologists must especially be aware of the options for screening, genetic counseling, and prenatal diagnosis of the disease. A multidisciplinary approach must be adopted for the management of these patients [8-10]. In 1994, Finlay et al. developed the Dermatology Life Quality Index (DLQI) [11,12]. This is a 10-item questionnaire that covers six domains, specifically regarding symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. In this study, we aimed to evaluate the psychological impact of NF1 on an Indian population, gauge their QoL, and understand the extent of disease burden by using the DLQI questionnaire.

Materials and methods

Study design This cross-sectional study enrolled 40 patients with NF1 reporting to the dermatology clinic in a tertiary hospital in western India, across a span of 24 months. The study was approved by the Research and Recognition Committee of Dr. D. Y. Patil Medical College, Hospital and Research Centre (approval number: IESC/PGS/2019/43). Data collection Socio-demographic and clinical information was obtained from the patients after due consent and documented in a pre-designed proforma. Clinical history and examination of patients were followed by evaluation of their QoL, using a validated DLQI questionnaire (10-item questionnaire) in languages comprehensible to them. Inclusion and exclusion criteria All individuals clinically suspected to have NF1 as per the criteria of the National Institute of Health were included in the study. Patients not consenting to participate were excluded from the study. Age, sex, disease duration, and the presence or absence of any other major illnesses were not considered for inclusion or exclusion. DLQI questionnaire Each question of the DLQI questionnaire has five possible responses: “not relevant,” “not at all,” “a little,” “a lot,” or “very much,” which are scored as 0, 0, 1, 2, and 3, respectively. Question 7 is scored differently, with “prevented work or studying” being given a score of 3 [13]. The DLQI questionnaire is presented in the Appendix. The final DLQI score was calculated as the sum of the scores of all questions, which has a range of 0-30. DLQI scores of 0-1, 2-5, 6-10, 11-20, and 21-30, respectively, correspond to having no, small, moderate, very large, and extremely large effect on the patient's life. Statistical analysis Data were entered in Microsoft Excel (Microsoft Corporation, Redmond, WA) and analyzed using the Statistical Package for the Social Sciences (SPSS) software version 20 (IBM Corp., Armonk, NY). Categorical variables were expressed in terms of frequency and percentage, whereas continuous variables were expressed as the mean and standard deviation (SD). For qualitative variables, the percentage and chi-square test were performed. Karl Pearson coefficient of correlation was also performed. A two-tailed probability value of 0.05 or less was considered statistically significant.

Results

This study included 40 patients with an age range of 6-65 (mean: 28.6) years, including 23 (57.5%) males and 17 (42.5%) females (Table 1). A family history of NF1 was positive in 19 (47.5%) patients, with seven (17.5%) patients reporting consanguineous marriage of their parents. Café-au-lait macules and neurofibromas, which were both seen in 38 (95%) patients, were the most commonly occurring lesions. Intertriginous freckling was seen in 28 (70%) patients, Lisch nodules in 19 (47.5%), plexiform neurofibromas in 15 (37.5%), and optic nerve tumors in one (2.5%) patient.
Table 1

Demographic factors of NF1 patients.

NF1, neurofibromatosis type 1.

FactorsVariantsn%
Age10 25
  11-20922.5
 21-301640
 31-40410
 41-50820
 >5112.5
GenderMale2357.5
 Female1742.5
Family history of NF1Positive1947.5
 Negative2152.5
Consanguineous marriage of parentsPresent717.5
 Absent3382.5

Demographic factors of NF1 patients.

NF1, neurofibromatosis type 1. The mean DLQI score was 12.35 ± 7.73, which reflects a significant degree of impact on the QoL of most patients. Table 2 demonstrates the various categories of DLQI scores obtained in our cohort.
Table 2

DLQI scores in NF1.

DLQI, Dermatology Life Quality Index; NF1, neurofibromatosis type 1.

DLQI categoriesn%
No effect on patient's life00
Small effect on patient's life1025
Moderate effect on patient's life1127.50
Very large effect on patient's life1025
Extremely large effect on patient's life922.50

DLQI scores in NF1.

DLQI, Dermatology Life Quality Index; NF1, neurofibromatosis type 1. Table 3 depicts the mean scores of answers to individual questions of the DLQI questionnaire. Impairment of QoL, evaluated via the DLQI questionnaire, revealed that question 2 (i.e., “Over the last week, how embarrassed or self-conscious have you been because of your skin?”) had the highest mean score of 1.9, followed by question 4 (i.e., “Over the last week, how much has your skin influenced the clothes you wear?”), with a score of 1.85. On the other hand, question 6, related to difficulties in playing any sports, had the lowest average score of 0.45.
Table 3

Mean scores of individual questions of DLQI.

DLQI, Dermatology Life Quality Index.

Question12345678910Total 
Mean11.90.651.850.950.451.81.430.871.4512.35
SD0.8940.9430.8230.9891.0470.7051.470.8911.0530.9217.738

Mean scores of individual questions of DLQI.

DLQI, Dermatology Life Quality Index. Tables 4, 5 demonstrate the comparison between the various demographic and clinical factors and DLQI categories. Age, presence of café‐au-lait macules, Lisch nodules, freckling, and plexiform neurofibromas had a significant negative correlation with QoL (p < 0.05). Gender, family history of the disease, and parental consanguinity did not have a significant correlation with QoL.
Table 4

Comparison between demographic factors and DLQI categories.

DLQI, Dermatology Life Quality Index; NF1, neurofibromatosis type 1.

 DLQI categoriesP-value
Small effect Moderate effect Very large effect Extremely large effect Total 
GenderMale767323p = 0.35
30.43%26.10%30.43%13.04%100.00%
Female353617
17.65%29.41%17.65%35.29%100.00%
 DLQI categoriesP-value
Small effect Moderate effect Very large effectExtremely large effectTotalp = 0.0015
Age1020002
 18.75%50.00%12.50%18.75%100.00%
31-4010034
25.00%0.00%0.00%75.00%100.00%
41-5010438
12.50%0.00%50.00%37.50%100.00%
>5100101
0.00%0.00%100.00%0.00%100.00%
 DLQI categoriesP-value
Small effect Moderate effect Very large effectExtremely large effect Totalp = 0.17
Family history of NF1Positive345719
15.79%21.05%26.32%36.84%100.00%
Negative775221
33.33%33.33%23.81%9.53%100.00%
 DLQI categoriesP-value
Small effect Moderate effect Very large effect Extremely large effect Totalp = 0.34
Consanguineous marriage of parentsPresent02237
0.00%28.57%28.57%42.86%100.00%
Absent1098633
30.30%27.28%24.24%18.18%100.00%
Table 5

Comparison between clinical features and DLQI categories.

DLQI, Dermatology Life Quality Index; CALMS, café‐au-lait macules; NFs- neurofibromas.

 DLQI categoriesP-value
Small effectModerate effectVery large effectExtremely large effectTotalp < 0.0001
CALMS1032005
60.00%40.00%0.00%0.00%100.00%
 11-25661215
40.00%40.00%6.67%13.33%100.00%
26-50036413
0.00%23.08%46.15%30.77%100.00%
>5000235
0.00%0.00%40.00%60.00%100.00%
 DLQI categoriesP-value
Small effectModerate effectVery large effectExtremely large effectTotalp < 0.01
NFs 1061108
75.00%12.50%12.50%0.00%100.00%
 11-25385420
15.00%40.00%25.00%20.00%100.00%
26-5001236
0.00%16.67%33.33%50.00%100.00%
>5000224
0.00%0.00%50.00%50.00%100.00%
 DLQI categoriesP-value
Small effectModerate effectVery large effectExtremely large effectTotalp < 0.001
Freckling Present in388928
10.71%28.57%28.57%32.15%100.00%
 DLQI categoriesP-value
Small effectModerate effectVery large effectExtremely large effectTotalp = 0.007
Lisch nodules Present in337619
15.79%15.79%36.84%31.58%100.00%
 DLQI categoriesP-value
Small effectModerate effectVery large effectExtremely large effectTotalp = 0.006
Plexiform NFsPresent in016815
0.00%6.67%40.00%53.33%100.00%

Comparison between demographic factors and DLQI categories.

DLQI, Dermatology Life Quality Index; NF1, neurofibromatosis type 1.

Comparison between clinical features and DLQI categories.

DLQI, Dermatology Life Quality Index; CALMS, café‐au-lait macules; NFs- neurofibromas.

Discussion

Our study cohort had a slight male predominance, which was also seen in a study by Purkait et al. on patients with neurocutaneous syndromes [2]. The most frequently occurring lesions in our study were café‐au-lait macules, seen in 95% of patients, which had a similar prevalence of 93% in a study by Lakshmanan et al. on NF1 patients in South India. Furthermore, their study demonstrated freckling in 90% of patients, whereas in our group, this occurred in 70%. A family history of NF1 was positive in 47.5% of our patients, in contrast to 33% of patients in their study [14]. Cutaneous neurofibromas were seen in 95% of our patients, similar to the findings of Lakshmanan et al. and Wolkenstein et al., with an occurrence of 96.6% and 91%, respectively [10,14]. The presence of plexiform neurofibromas in our study was comparable to that of a study by Huson et al. (37.5% vs. 32%, respectively) [15]. On the other hand, Lisch nodules were present in 47.5% of patients in our study, which is lower than that in a study from Northwest England and a study by Friedman et al. (63% and 57%, respectively) [16,17]. The mean DLQI was 12.35 ± 7.73, with higher QoL impairment in females (14 ± 8.66) than in males (11.13 ± 6.72). Higher DLQI scores were observed with more extensive skin involvement, female gender, and the presence of plexiform neurofibromas. Upon analysis of DLQI scores, NF1 had no effect in zero cases but had a small, moderate, very large, and extremely large effect in 10 (25%), 11 (27.5%), 10 (25%), and nine (22.5%) patients, respectively. Similar studies from Italy and America demonstrated that patients with more visible lesions had a greater impact on the emotional aspect of their QoL [18,19]. A study from Brazil concluded that patients were significantly concerned about transmitting the disease to their progeny and expressed difficulties in obtaining appropriate treatment [20]. Various studies on the QoL of NF1 patients done in a few countries also reported a negative effect on QoL across multiple aspects of life [21,22]. A Canadian study of 176 patients reported that patients' mental well-being and overall QoL were influenced greatly by their perceived physical appearance [23]. The presence of café-au-lait macules, Lisch nodules, plexiform neurofibromas, and freckling had a significant negative correlation with QoL (P < 0.05). Individual questions of the DLQI questionnaire demonstrated the highest mean scores for questions 2 and 4 (1.9 and 1.85, respectively), followed by question 10 (1.8), indicating that self-consciousness, embarrassment, choice of clothing, and time taken by treatment were aspects of their lives most affected by the disease. Questions 3 and 6, pertaining to difficulty in playing sports and shopping/gardening, had the lowest mean scores, signifying a lower impact on these spheres of a patient’s life. Study limitations More extensive questionnaires like the Skindex and 36-Item Short Form Survey (SF-36) were not used to evaluate the QoL due to the poor compliance of patients and the relatively lengthy nature of those questionnaires.

Conclusions

NF1 has a significant effect on patients' QoL due to changes in their appearance and societal stigma. Patients with comparatively fewer lesions can also experience a drastic impairment in their QoL, and their mental health must be considered just as much as a patient with extensive lesions. Early identification of patients with impaired QoL should prompt adequate therapeutic counseling and reference for a multidisciplinary approach.
  20 in total

1.  Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales.

Authors:  S M Huson; P S Harper; D A Compston
Journal:  Brain       Date:  1988-12       Impact factor: 13.501

2.  Gender response to neurofibromatosis 1.

Authors:  J Ablon
Journal:  Soc Sci Med       Date:  1996-01       Impact factor: 4.634

3.  Impact of neurofibromatosis 1 on Quality of Life: a cross-sectional study of 176 American cases.

Authors:  Patricia Z Page; Grier P Page; Emmanuel Ecosse; Bruce R Korf; Alain Leplege; Pierre Wolkenstein
Journal:  Am J Med Genet A       Date:  2006-09-15       Impact factor: 2.802

4.  Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients.

Authors:  J M Friedman; P H Birch
Journal:  Am J Med Genet       Date:  1997-05-16

5.  The Patients' Experiences of Burden of Neurofibromatosis: A Qualitative Study.

Authors:  Samira Foji; Eesa Mohammadi; Akram Sanagoo; Leila Jouybari
Journal:  Iran J Nurs Midwifery Res       Date:  2021-07-20

6.  Detecting anxiety symptoms in children and youths with neurofibromatosis type I.

Authors:  Augusto Pasini; Adriana Lo-Castro; Loredana Di Carlo; Mariabernarda Pitzianti; Martina Siracusano; Caterina Rosa; Cinzia Galasso
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-08-22       Impact factor: 3.568

7.  Quality of Life in Adults with Neurofibromatosis 1 in Brazil.

Authors:  Natália Parenti Bicudo; Balduíno Ferreira de Menezes Neto; Lucimar Retto da Silva de Avó; Carla Maria Ramos Germano; Débora Gusmão Melo
Journal:  J Genet Couns       Date:  2016-03-05       Impact factor: 2.537

8.  The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions.

Authors:  Roderick J Hay; Nicole E Johns; Hywel C Williams; Ian W Bolliger; Robert P Dellavalle; David J Margolis; Robin Marks; Luigi Naldi; Martin A Weinstock; Sarah K Wulf; Catherine Michaud; Christopher J L Murray; Mohsen Naghavi
Journal:  J Invest Dermatol       Date:  2013-10-28       Impact factor: 8.551

9.  Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.

Authors:  Geohana Hamoy-Jimenez; Raymond Kim; Suganth Suppiah; Gelareh Zadeh; Vera Bril; Carolina Barnett
Journal:  Neurooncol Adv       Date:  2020-01-10

10.  Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome.

Authors:  Daphne L Wang; Kelly B Smith; Sonia Esparza; Fawn A Leigh; Alona Muzikansky; Elyse R Park; Scott R Plotkin
Journal:  Genet Med       Date:  2012-08-09       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.